Guardant Health (NASDAQ:GH) Insider Sells 63,605 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the sale, the insider directly owned 65,374 shares in the company, valued at approximately $11,086,122.92. This represents a 49.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Chris Freeman also recently made the following trade(s):

• On Friday, May 22nd, Chris Freeman sold 24,406 shares of Guardant Health stock. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02.

Guardant Health Price Performance

Shares of GH stock traded down $2.12 on Tuesday, hitting $165.09. 1,300,019 shares of the company’s stock were exchanged, compared to its average volume of 2,305,035. The company has a 50 day moving average of $147.78 and a 200 day moving average of $115.59. The stock has a market cap of $22.16 billion, a P/E ratio of -47.30 and a beta of 1.60. Guardant Health, Inc. has a 12 month low of $53.40 and a 12 month high of $176.58.

Institutional Trading of Guardant Health

A number of hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in shares of Guardant Health by 14.5% during the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock worth $145,000 after purchasing an additional 122 shares during the last quarter. First Pacific Financial raised its holdings in Guardant Health by 33.1% in the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock valued at $52,000 after buying an additional 139 shares during the last quarter. Xponance LLC raised its holdings in Guardant Health by 2.1% in the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after buying an additional 199 shares during the last quarter. Danske Bank A S boosted its position in Guardant Health by 20.0% during the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after buying an additional 200 shares during the period. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna boosted its position in Guardant Health by 1.9% during the 4th quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock worth $1,124,000 after buying an additional 200 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GH has been the subject of a number of research reports. UBS Group set a $150.00 target price on shares of Guardant Health in a report on Wednesday, June 24th. Bank of America upped their price objective on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Royal Bank Of Canada increased their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. TD Cowen raised their target price on shares of Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Canaccord Genuity Group boosted their target price on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and a consensus price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.